Orphan Drugs and Rare Diseases

Wednesday, November 28 – Thursday, November 29 2012

Location: Hyatt Regency, Boston, MA

Developing drugs and investing in research and development can be risky business in general, and it can be even more so for small populations with unique disease states. Our faculty of leading experts from Pfizer, Shire, Medicis, GSK, Emergent BioSolutions and many more will give you strategies to offset potential risks inherent to orphan drug development including:

  • Understanding and factoring in the unique incentives, including favorable exclusivity, pricing, and tax benefits, for companies who decide to pursue designation
  • Replenishing product pipelines in the face of the patent cliff through novel therapies
  • Preparing for eventual pharmacovigilance and labeling issues downstream as designation takes off
  • Designing clinical trials end points and proving safety and efficacy in a smaller population
  • Protecting orphan drug status and keeping competitors at bay post-Makena

** MassBio members receive a $300 discount! Reference discount code "MASSBIO 300" at registration. **

For More Information & to register, visit: http://www.americanconference.com/2013/793/orphan-drugs-and-rare-diseases

Share MassBio